IP Library Granted Patent US 8,759,066
Granted Patent B2
US 8,759,066 · App. 12/935,235 · Granted Jun 24, 2014

Thrombin activator compositions and methods of making and using the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,759,066
App. No.
12/935,235
Granted
Jun 24, 2014
Kind
B2
Abstract

Disclosed are compositions for activating thrombin precursors to thrombin. The compositions provided include polypeptide compositions wherein the pre-pro-sequence comprises a thrombin cleavage site. The compositions provided also include polynucleotides encoding said polypeptides and recombinant systems for expressing said polypeptides. This disclosure also relates to methods for producing said compositions, recovering said compositions, activating said compositions purifying said compositions and producing active thrombin molecules using the active form of said compositions.

Claims (13)

1. A recombinant metalloprotease pre-pro-activator comprising, from an amino-terminal position to a carboxyl-terminal position, a pre-pro leader that shares at least 60% sequence identity with the pre-pro leader from Echis carinatus ecarin wild-type metalloprotease pre-pro-activator; a thrombin cleavage site consisting of a glycine, a proline, and an arginine; and a mature activator that shares at least 60% sequence identity with the mature activator from the Echis carinatus ecarin wild-type metalloprotease pre-pro-activator.

2. The recombinant metalloprotease pre-pro-activator of claim 1 , wherein the pre-pro leader shares at least 60% sequence identity with amino acid residues 1-187 of SEQ ID NO:100; and wherein the mature activator shares at least 60% sequence identity with amino acid residues 191-616 of SEQ ID NO:100.

3. The recombinant metalloprotease pre-pro-activator of claim 1 , wherein said pre-pro-activator shares at least 90% sequence identity with the amino acid sequence of residues 1-616 of SEQ ID NO:2.

4. The recombinant metalloprotease pre-pro-activator of claim 1 , wherein said pre-pro-activator shares at least 99% sequence identity with the amino acid sequence of residues 1-616 of SEQ ID NO:2.

5. The recombinant metalloprotease pre-pro-activator as in claim 1 , further comprising an affinity tag positioned carboxyl-terminal to the mature activator.

6. The recombinant metalloprotease pre-pro-activator of claim 5 , wherein said affinity tag is a histidine tag.

7. The recombinant metalloprotease pre-pro-activator as in claim 1 , wherein said pre-pro-activator consists essentially of the pre-pro leader, the thrombin cleavage site, and the mature activator.

8. The recombinant metalloprotease pre-pro-activator as in claim 1 , wherein said pre-pro leader comprises at least thirty-five contiguous amino acid residues from amino acid residues 1-187 of SEQ ID NO:100.

9. The recombinant metalloprotease pre-pro-activator as in claim 1 , wherein said pre-pro leader comprises amino acid residues 153-187 of SEQ ID NO:100.

10. The recombinant metalloprotease pre-pro-activator as in claim 1 , wherein said pre-pro leader comprises amino acid residues 1-187 of SEQ ID NO:100.

11. A recombinant metalloprotease pre-pro-activator comprising the amino acid sequence of residues 1-616 of SEQ ID NO:2.

12. An isolated pre-pro-activator polypeptide produced by transfecting a host cell with an expression vector comprising a polynucleotide sequence encoding a pre-pro-activator as in claim 1 ; and expressing the encoded pre-pro-activator from said expression vector.

13. The recombinant metalloprotease pre-pro-activator of claim 1 , wherein said mature activator comprises amino acid residues 188-616 of SEQ ID NO:2, 189-616 of SEQ ID NO:2, 190-616 of SEQ ID NO:2, or 191-616 of SEQ ID NO:2.

Assignments (8)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 043596, FRAME 0259 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065610/0324 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2018
From: MALLINCKRODT PHARMA IP TRADING DAC
To: BAXTER INTERNATIONAL, INC.
Reel/Frame 046067/0652 →
CORRECTIVE ASSIGNMENT TO CORRECT THE SIGNATORY PAGES ON SUPPORTING DOCUMENT PREVIOUSLY RECORDED AT REEL: 043723 FRAME: 0478. ASSIGNOR(S) HEREBY CONFIRMS THE NUNC PRO TUNC ASSIGNMENT. Recorded Oct 3, 2017
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: MALLINCKRODT PHARMA IP TRADING D.A.C.
Reel/Frame 044570/0091 →
NUNC PRO TUNC ASSIGNMENT Recorded Sep 28, 2017
From: THE MEDICINES COMPANY
To: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 043723/0188 →
NUNC PRO TUNC ASSIGNMENT Recorded Sep 28, 2017
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: MALLINCKRODT PHARMA IP TRADING D.A.C.
Reel/Frame 043723/0478 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Aug 18, 2017
From: MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 043596/0259 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2015
From: ZYMOGENETICS, LLC
To: THE MEDICINES COMPANY
Reel/Frame 035988/0724 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2012
From: ZYMOGENETICS, INC.
To: ZYMOGENETICS, LLC
Reel/Frame 029406/0917 →